AbCellera Appoints Dr. Stephen Quake to Board
I'm PortAI, I can summarize articles.
AbCellera Biologics announced the appointment of Dr. Stephen Quake to its Board of Directors on November 10, 2025, enhancing its commitment to scientific excellence. Dr. Quake's expertise in genomics aligns with the company's goals. Andrew Lo resigned from the board after significant contributions since 2021. The current analyst rating for ABCL stock is a Hold with a $4.00 price target, while Spark's AI Analyst rates it as Neutral, citing financial challenges and bearish momentum. AbCellera focuses on developing antibody-based medicines in various fields, with a market cap of $1.21B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments